Physiology and Pathology of the Female Reproductive Axis

Williams Textbook of Endocrinology

Volumn , Issue , 2015, Pages 589-663

  Bulun, Serdar E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85167774371     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-29738-7.00017-4     Document Type: Chapter

References (411)

1. CK Cheng and PC Leung (2005) Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 26 283-306
2. PH Seeburg, AJ Mason, TA Stewart and K Nikolics (1987) The mammalian GnRH gene and its pivotal role in reproduction. Recent Prog Horm Res 43 69-98
3. K Nikolics, AJ Mason, E Szonyi, et al. (1985) A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone. Nature 316 511-517
4. J Ackland, K Nikolics, P Seeburg, et al. (1988) Molecular forms of gonadotropin-releasing hormone associated peptide (GAP): changes within the rat hypothalamus and release from hypothalamic cells in vitro. Neuroendocrinology 48 376-386
5. HG Kim, B Bhagavath and LC Layman (2008) Clinical manifestations of impaired GnRH neuron development and function. Neurosignals 16 165-182
6. FA Costa-Barbosa, R Balasubramanian, KW Keefe, et al. (2013) Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. J Clin Endocrinol Metab 98 E943-E953
7. E Knobil (1980) The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 36 53-88
8. DA Van Vugt, WD Diefenbach, E Alston and M Ferin (1985) Gonadotropin-releasing hormone pulses in third ventricular cerebrospinal fluid of ovariectomized rhesus monkeys: correlation with luteinizing hormone pulses. Endocrinology 117 1550-1558
9. KM Gross, AM Matsumoto, MB Southworth and WJ Bremner (1985) Evidence for decreased luteinizing hormone-releasing hormone pulse frequency in men with selective elevations of follicle-stimulating hormone. J Clin Endocrinol Metab 60 197-202
10. DJ Haisenleder, AC Dalkin, GA Ortolano, et al. (1991) A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology 128 509-517
11. N Reame, S Sauder, G Case, et al. (1985) Pulsatile gonadotropin secretion in women with hypothalamic amenorrhea: evidence that reduced frequency of gonadotropin secretion is the mechanism of persistent anovulation. J Clin Endocrinol Metab 61 851-858
12. RL Goodman, DB Parfitt, NP Evans, et al. (1995) Endogenous opioid peptides control the amplitude and shape of gonadotropin-releasing hormone pulses in the ewe. Endocrinology 136 2412-2420
13. AE Herbison (1997) Noradrenergic regulation of cyclic GnRH secretion. Rev Reprod 2 1-6
14. PR Gindoff and M Ferin (1987) Endogenous opioid peptides modulate the effect of corticotropin-releasing factor on gonadotropin release in the primate. Endocrinology 121 837-842
15. J Rabinovici, P Rothman, S Monroe, et al. (1992) Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. J Clin Endocrinol Metab 75 1220-1225
16. L Wildt, G Leyendecker, T Sir-Petermann and S Waibel-Treber (1993) Treatment with naltrexone in hypothalamic ovarian failure: induction of ovulation and pregnancy. Hum Reprod 8 350-358
17. SL Petersen, EN Ottem and CD Carpenter (2003) Direct and indirect regulation of gonadotropin-releasing hormone neurons by estradiol. Biol Reprod 69 1771-1778
18. MB Yilmaz, A Wolfe, YH Cheng, et al. (2009) Aromatase promoter I.f is regulated by estrogen receptor alpha (ESR1) in mouse hypothalamic neuronal cell lines. Biol Reprod 81 956-965
19. RF Casper (2007) Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol 106 71-75
20. SB Seminara, S Messager, EE Chatzidaki, et al. (2003) The GPR54 gene as a regulator of puberty. N Engl J Med 349 1614-1627
21. N de Roux, E Genin, JC Carel, et al. (2003) Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 100 10972-10976
22. WH Colledge (2009) Kisspeptins and GnRH neuronal signalling. Trends Endocrinol Metab 20 115-121
23. SM Popa, DK Clifton and RA Steiner (2008) The role of kisspeptins and GPR54 in the neuroendocrine regulation of reproduction. Annu Rev Physiol 70 213-238
24. DJ Handelsman and RS Swerdloff (1986) Pharmacokinetics of gonadotropin-releasing hormone and its analogs. Endocr Rev 7 95-105
25. MJ Karten and JE Rivier (1986) Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 7 44-66
26. A Lemay, R Maheux, N Faure, et al. (1984) Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41 863-871
27. BR Carr, NA Breslau, C Givens, et al. (1995) Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J Clin Endocrinol Metab 80 1169-1178
28. C Cann, M Martin, H Genant and R Jaffe (1984) Decreased spinal mineral content in amenorrheic women. JAMA 251 626-629
29. WH Matta, RW Shaw, R Hesp and R Evans (1988) Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol (Oxf) 29 45-51
30. E Surrey (1999) Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group. Fertil Steril 71 420-424
31. S Pavlou, C Debold, D Island, et al. (1986) Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men. J Clin Endocrinol Metab 63 303-308
32. SN Pavlou, G Wakefield, NL Schlechter, et al. (1989) Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men. J Clin Endocrinol Metab 68 446-454
33. MC Edelstein, K Gordon, RF Williams, et al. (1990) Single dose long-term suppression of testosterone secretion by a gonadotropin-releasing hormone antagonist (Antide) in male monkeys. Contraception 42 209-214
34. HM Behre, S Kliesch, G Puhse, et al. (1997) High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men. J Clin Endocrinol Metab 82 1403-1408
35. HG Al-Inany, MA Youssef, M Aboulghar, et al. (2011) Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev (5), CD001750
36. GV Childs, C Hyde, Z Naor and K Catt (1983) Heterogeneous luteinizing hormone and follicle-stimulating hormone storage patterns in subtypes of gonadotropes separated by centrifugal elutriation. Endocrinology 113 2120-2128
37. GV Childs (1986) Functional ultrastructure of gonadotropes: a review. Curr Top Neuroendocrinol 7 49-97
38. RP Millar, ZL Lu, AJ Pawson, et al. (2004) Gonadotropin-releasing hormone receptors. Endocr Rev 25 235-275
39. SD Gharib, ME Wierman, MA Shupnik and WW Chin (1990) Molecular biology of the pituitary gonadotropins. Endocr Rev 11 177-199
40. K Talmadge, NC Vamvakopoulos and JC Fiddes (1984) Evolution of the genes for the beta subunits of human chorionic gonadotropin and luteinizing hormone. Nature 307 37-40
41. JL Jameson, CB Becker, CM Lindell and JF Habener (1988) Human follicle-stimulating hormone beta-subunit gene encodes multiple messenger ribonucleic acids. Mol Endocrinol 2 806-815
42. L Jameson, WW Chin, AN Hollenberg, et al. (1984) The gene encoding the beta-subunit of rat luteinizing hormone. Analysis of gene structure and evolution of nucleotide sequence. J Biol Chem 259 15474-15480
43. APN Themmen and IT Huhtaniemi (2000) Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 21 551-583
44. M Shupnik (1996) Gonadotropin gene modulation by steroids and gonadotropin-releasing hormone. Biol Reprod 54 279-286
45. MA Edson, AK Nagaraja and MM Matzuk (2009) The mammalian ovary from genesis to revelation. Endocr Rev 30 624-712
46. RA Abbud, RK Ameduri, JS Rao, et al. (1999) Chronic hypersecretion of luteinizing hormone in transgenic mice selectively alters responsiveness of the alpha-subunit gene to gonadotropin-releasing hormone and estrogens. Mol Endocrinol 13 1449-1459
47. VG Thackray, PL Mellon and D Coss (2009) Hormones in synergy: regulation of the pituitary gonadotropin genes. Mol Cell Endocrinol 314 192-203
48. DJ Bernard, J Fortin, Y Wang and P Lamba (2010) Mechanisms of FSH synthesis: what we know, what we don't, and why you should care. Fertil Steril 93 2465-2485
49. R de Leeuw, J Mulders, G Voortman, et al. (1996) Structure-function relationship of recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 2 361-369
50. Y Choi and A Rajkovic (2006) Genetics of early mammalian folliculogenesis. Cell Mol Life Sci 63 579-590
51. E Di Pasquale, P Beck-Peccoz and L Persani (2004) Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 75 106-111
52. E Witschi (1948) Migration of the germ cells of human embryos from the yolk sac to the primitive gonadal folds. Contrib Embryol 32 67
53. S Chuva, S van den Driesche, S Carvalho, et al. (2005) Altered primordial germ cell migration in the absence of transforming growth factor β signaling via ALK5. Dev Biol 284(1), 194-203
54. D Farini, G La Sala, M Tedesco and M De Felici (2007) Chemoattractant action and molecular signaling pathways of Kit ligand on mouse primordial germ cells. Dev Biol 306(2), 572-583
55. O Oktem and K Oktay (2008) The ovary: anatomy and function throughout human life. Ann N Y Acad Sci 1127 1-9
56. R Himelstein-Braw, AG Byskov, H Peters and M Faber (1976) Follicular atresia in the infant human ovary. J Reprod Fertil 46 55-59
57. AM Simon, DA Goodenough, E Li and DL Paul (1997) Female infertility in mice lacking connexin 37. Nature 385 525-529
58. L Espey (1974) Ovarian proteolytic enzymes and ovulation. Biol Reprod 10 216-235
59. LC Zoller and J Weisz (1979) A quantitative cytochemical study of glucose-6-phosphate dehydrogenase and delta 5-3 beta-hydroxysteroid dehydrogenase activity in the membrana granulosa of the ovulable type of follicle of the rat. Histochemistry 62 125-135
60. C Magnusson, H Billig, P Eneroth, et al. (1982) Comparison between the progestin secretion responsiveness to gonadotrophins of rat cumulus and mural granulosa cells in vitro. Acta Endocrinol (Copenh) 101 611-616
61. Y Hu, S Ghosh, A Amleh, et al. (2005) Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 24 8343-8348
62. M Lu, D Chen, Z Lin, et al. (2006) BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. J Clin Endocrinol Metab 91 4514-4519
63. G Erickson, D Magoffin, C Dyer and C Hofeditz (1985) The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev 6 371-399
64. A Gougeon (1996) Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev 17 121-155
65. I Schipper, W Hop and B Fauser (1998) The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development. J Clin Endocrinol Metab 83 1292-1298
66. H Peters and KP McNatty (1980) The Ovary: A Correlation of Structure and Function in Mammals. Berkeley, CA: University of California Press 12; 34
67. JL Tilly, KI Kowalski, AL Johnson and AJ Hsueh (1991) Involvement of apoptosis in ovarian follicular atresia and postovulatory regression. Endocrinology 129 2799-2801
68. S Bauminger and H Lindner (1975) Periovulatory changes in ovarian prostaglandin formation and their hormonal control in the rat. Prostaglandins 9 737-751
69. A Tsafriri, HR Lindner, U Zor and SA Lamprecht (1972) Physiological role of prostaglandins in the induction of ovulation. Prostaglandins 2 1-10
70. L Bjersing and S Cajander (1974) Ovulation and the mechanism of follicle rupture. IV. Ultrastructure of membrana granulosa of rabbit graafian follicles prior to induced ovulation. Cell Tissue Res 153 1-14
71. WH Beers, S Strickland and E Reich (1975) Ovarian plasminogen activator: relationship to ovulation and hormonal regulation. Cell 6 387-394
72. JL Frederick, T Shimanuki and GS diZerega (1984) Initiation of angiogenesis by human follicular fluid. Science 224 389-390
73. BR Kamat, LF Brown, EJ Manseau, et al. (1995) Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol 146 157-165
74. A Ohara, T Mori, S Taii, et al. (1965) Functional differentiation in steroidogenesis of two types of luteal cells isolated from mature human corpora lutea of menstrual cycle. J Clin Endocrinol Metab 65 1192-1200
75. B Carr, P MacDonald and E Simpson (1982) The role of lipoproteins in the regulation of progesterone secretion by the human corpus luteum. Fertil Steril 38 303-311
76. WC Duncan, AS McNeilly, HM Fraser and PJ Illingworth (1996) Luteinizing hormone receptor in the human corpus luteum: lack of down-regulation during maternal recognition of pregnancy. Hum Reprod 11 2291-2297
77. JF Strauss 3rd, LK Christenson, L Devoto and F Martinez (2000) Providing progesterone for pregnancy: control of cholesterol flux to the side-chain cleavage system. J Reprod Fertil Suppl 55 3-12
78. R Casper and S Yen (1979) Induction of luteolysis in the human with a long acting analog of luteinizing hormone-releasing factor. Science 205 408-410
79. JN Schoonmaker, W Victery and FJ Karsch (1981) A receptive period for estradiol-induced luteolysis in the rhesus monkey. Endocrinology 108 1874-1877
80. JP O'Grady, EI Kohorn, RH Glass, et al. (1972) Inhibition of progesterone synthesis in vitro by prostaglandin F2. J Reprod Fertil 30 153-156
81. T Shikone, M Yamoto, K Kokawa, et al. (1996) Apoptosis of human corpora lutea during cyclic luteal regression and early pregnancy. J Clin Endocrinol Metab 81 2376-2380
82. M Bortolussi, G Marini and A Dal Lago (1977) Autoradiographic study of the distribution of LH (hCG) receptors in the ovary of untreated and gonadotrophin-primed immature rats. Cell Tissue Res 183 329-342
83. A Nimrod, GF Erickson and KJ Ryan (1976) A specific FSH receptor in rat granulosa cells: properties of binding in vitro. Endocrinology 98 56-64
84. A Nimrod, E Bedrak and SA Lamprecht (1977) Appearance of LH-receptors and LH-stimulable cyclic AMP accumulation in granulosa cells during follicular maturation in the rat ovary. Biochem Biophys Res Commun 78 977-984
85. AJ Zeleznik, AR Midgley Jr and LE Reichert Jr (1974) Granulosa cell maturation in the rat: increased binding of human chorionic gonadotropin following treatment with follicle-stimulating hormone in vivo. Endocrinology 95 818-825
86. J Richards, J Ireland, M Rao, et al. (1976) Ovarian follicular development in the rat: hormone receptor regulation by estradiol, follicle-stimulating hormone and luteinizng hormone. Endocrinology 99 1562-1570
87. JF Couse and KS Korach (1999) Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20 358-417
88. AW Brandenberger, MK Tee and RB Jaffe (1998) Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 83 1025-1028
89. ER Simpson, MS Mahendroo, GD Means, et al. (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15 342-355
90. JS Richards and SA Pangas (2010) The ovary: basic biology and clinical implications. J Clin Invest 120 963-972
91. JJ Barlow, K Emerson Jr and BN Saxena (1969) Estradiol production after ovariectomy for carcinoma of the breast. N Engl J Med 280 633-637
92. DT Baird and IS Fraser (1975) Concentrations of oestrone and oestradiol in follicular fluid and ovarian venous blood of women. Clin Endocrinol 4 259-266
93. SE Bulun, Z Lin, G Imir, et al. (2005) Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57 359-383
94. M Mahendroo and D Russell (1999) Male and female isoenzymes of steroid 5alpha-reductase. Rev Reprod 4 179-183
95. WL Miller and JF Strauss 3rd. (1999) Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR. J Steroid Biochem Mol Biol 69 131-141
96. SE Pollack, EE Furth, CB Kallen, et al. (1997) Localization of the steroidogenic acute regulatory protein in human tissues. J Clin Endocrinol Metab 82 4243-4251
97. S Leers-Sucheta, K Morohashi, JI Mason and MH Melner (1997) Synergistic activation of the human type II 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase promoter by the transcription factor steroidogenic factor-1/adrenal 4-binding protein and phorbol ester. J Biol Chem 272 7960-7967
98. NA Hanley, Y Ikeda, X Luo and KL Parker (2000) Steroidogenic factor 1 (SF-1) is essential for ovarian development and function. Mol Cell Endocrinol 163 27-32
99. JJ Kim, T Kurita and SE Bulun (2013) Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 34 130-162
100. SE Bulun (2014) Aromatase and estrogen receptor alpha deficiency. Fertil Steril 101 323-329
101. H Peltoketo, V Luu-The, J Simard and J Adamski (1999) 17Beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol 23 1-11
102. Y Makanji, J Zhu, R Mishra, et al. (2014) Inhibin at 90: from discovery to clinical application, a historical review. Endocr Rev 35(5), 747-794
103. N Peng, JW Kim, WE Rainey, et al. (2003) The role of the orphan nuclear receptor, liver receptor homologue-1, in the regulation of human corpus luteum 3beta-hydroxysteroid dehydrogenase type II. J Clin Endocrinol Metab 88 6020-6028
104. EY Adashi, CE Resnick, AJ D'Ercole, et al. (1985) Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev 6 400-420
105. J Kwintkiewicz and LC Giudice (2009) The interplay of insulin-like growth factors, gonadotropins, and endocrine disruptors in ovarian follicular development and function. Semin Reprod Med 27 43-51
106. NP Groome, PJ Illingworth, M O'Brien, et al. (1996) Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 81 1401-1405
107. A Dunaif (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 774-800
108. S Franks, J Stark and K Hardy (2008) Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 14 367-378
109. AT Konkle and MM McCarthy (2011) Developmental time course of estradiol, testosterone, and dihydrotestosterone levels in discrete regions of male and female rat brain. Endocrinology 152 223-235
110. Z Lin, S Reierstad, CC Huang and SE Bulun (2007) Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res 67 5017-5024
111. R Azziz, E Carmina and ME Sawaya (2000) Idiopathic hirsutism. Endocr Rev 21 347-362
112. K Diedrich, BC Fauser, P Devroey, et al. (2007) The role of the endometrium and embryo in human implantation. Hum Reprod Update 13 365-377
113. G Dallenbach-Hellweg (2010) Normal endometrium. G Dallenbach-Hellweg (Ed.) Atlas of Histopathology Berlin, Germany: Springer-Verlag
114. CE Gargett, KE Schwab, RM Zillwood, et al. (2009) Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium. Biol Reprod 80 1136-1145
115. J Markee (1940) Menstruation in intraocular endometrial transplants in the rhesus monkey. Contrib Embryol 28 219
116. J Markee (1948) Morphological basis for menstrual bleeding: relation of regression to the initiation of bleeding. Bull N Y Acad Med 36 153
117. RW Noyes, AT Hertig and J Rock (1950) Dating the endometrial biopsy. Fertil Steril 1 3-25
118. M Sauer, R Paulson and R Lobo (1992) Reversing the natural decline in human fertility. An extended clinical trial of oocyte donation to women of advanced reproductive age. JAMA 268 1275-1279
119. Z Rosenwaks (1987) Donor eggs: their application in modern reproductive technologies. Fertil Steril 47 895-909
120. PS Cooke, DL Buchanan, P Young, et al. (1997) Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci U S A 94 6535-6540
121. S Matsuzaki, T Fukaya, T Suzuki, et al. (1999) Oestrogen receptor alpha and beta mRNA expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod 559-564
122. P Cooke, D Buchanan, D Lubahn and G Cunha (1998) Mechanism of estrogen action: lessons from the estrogen receptor-alpha knockout mouse. Biol Reprod 59 470-475
123. JS Carroll, XS Liu, AS Brodsky, et al. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122(1), 33-43
124. GR Attia, K Zeitoun, D Edwards, et al. (2000) Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab 85 2897-2902
125. P Yin, D Roqueiro, L Huang, et al. (2012) Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells. PLoS ONE 7 e29021
126. L Tseng and E Gurpide (1975) Effects of progestins on estradiol receptor levels in human endometrium. J Clin Endocrinol Metab 41 402-404
127. L Tseng and H Liu (1981) Stimulation of acylsulfotransferase activity by progestin in human endometrium in vitro. J Clin Endocrinol Metab 53 418-421
128. S Yang, Z Fang, B Gurates, et al. (2001) Stromal progesterone receptors mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of estradiol. Mol Endocrinol 15 2093-2105
129. PA Bergh and D Navot (1992) The impact of embryonic development and endometrial maturity on the timing of implantation. Fertil Steril 58 537-542
130. A Hertig, J Rock and E Adams (1956) A description of 34 human ova within the first 17 days of development. Am J Anat 98 435
131. RD Langer, JJ Pierce, KA O'Hanlan, et al. (1997) Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med 337 1792-1798
132. HL Sheehan (1971) The recognition of chronic hypopituitarism resulting from postpartum pituitary necrosis. Am J Obstet Gynecol 111 852-854
133. J Simpson, A Christakos, M Horwith, et al. (1971) Gonadal dysgenesis in individuals with apparently normal chromosomal complements: tabulation of cases and compilation of genetic data. Birth Defects Orig Artic Ser 7(6), 215-228
134. WM Hague, J Adams, ST Reeders and HS Jacobs (1989) 45 X Turner's syndrome in association with polycystic ovaries. Case report. Br J Obstet Gynaecol 96 613-618
135. JG Asherman (1948) Amenorrhoea traumatica (atretica). J Obstet Gynaecol Br Emp 55 23-30
136. W Marshall and JM Tanner (1969) Variations in patterns of pubertal changes in girls. Arch Dis Child 44 291-303
137. M Filicori, N Santoro, GR Merriam and WF Crowley Jr (1986) Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab 62 1136-1144
138. JH Liu and AH Bill (2008) Stress-associated or functional hypothalamic amenorrhea in the adolescent. Ann N Y Acad Sci 1135 179-184
139. HJ Klinefelter, F Albrigh and GC Griswold (1943) Experience with a quantitative test for normal or decreased amounts of follicle-stimulating hormone in urine in endocrinological diagnosis. J Clin Endocrinol Metab 3 529-544
140. SA Khoury, NE Reame, RP Kelch and JC Marshall (1987) Diurnal patterns of pulsatile luteinizing hormone secretion in hypothalamic amenorrhea: reproducibility and responses to opiate blockade and an alpha 2-adrenergic agonist. J Clin Endocrinol Metab 64 755-762
141. S Yen, R Rebar and G Vandenberg (1973) Hypothalamic amenorrhea and hypogonadotropism: responses to synthetic LRF. J Clin Endocrinol Metab 36 811
142. SK Han and AE Herbison (2008) Norepinephrine suppresses gonadotropin-releasing hormone neuron excitability in the adult mouse. Endocrinology 149 1129-1135
143. P Grachev, XF Li, JS Kinsey-Jones, et al. (2012) Suppression of the GnRH pulse generator by neurokinin B involves a kappa-opioid receptor-dependent mechanism. Endocrinology 153 4894-4904
144. J Ropert, M Quigley and S Yen (1981) Endogenous opiates modulate pulsatile luteinizing hormone release in humans. J Clin Endocrinol Metab 52 583-585
145. AD Genazzani, F Petraglia, M Gastaldi, et al. (1995) Naltrexone treatment restores menstrual cycles in patients with weight loss-related amenorrhea. Fertil Steril 64 951-956
146. H Selye (1936) The stress syndrome. Nature 138 32
147. BY Suh, JH Liu, SL Berga, et al. (1988) Hypercortisolism in patients with functional hypothalamic-amenorrhea. J Clin Endocrinol Metab 66 733-739
148. E Xiao, J Luckhaus, W Niemann and M Ferin (1989) Acute inhibition of gonadotropin secretion by corticotropin-releasing hormone in the primate: are the adrenal glands involved? Endocrinology 124 1632-1637
149. C Rivier and W Vale (1984) Influence of corticotropin-releasing factor on reproductive functions in the rat. Endocrinology 114 914-921
150. R Matteri, G Moberg and J Watson (1986) Adrenocorticotropin-induced changes in ovine pituitary gonadotropin secretion in vitro. Endocrinology 118 2091-2096
151. F Kamel and CL Kubajak (1987) Modulation of gonadotropin secretion by corticosterone: interaction with gonadal steroids and mechanism of action. Endocrinology 121 561-568
152. CK Welt, JL Chan, J Bullen, et al. (2004) Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351 987-997
153. LF Schneider, SE Monaco and MP Warren (2008) Elevated ghrelin level in women of normal weight with amenorrhea is related to disordered eating. Fertil Steril 90 121-128
154. JE Morley and AS Levine (1980) Stress-induced eating is mediated through endogenous opiates. Science 209 1259-1261
155. NA Rigotti, RM Neer, SJ Skates, et al. (1991) The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 265 1133-1138
156. RE Frisch, G Wyshak and L Vincent (1980) Delayed menarche and amenorrhea in ballet dancers. N Engl J Med 303 17-19
157. RE Frisch, AV Gotz-Welbergen, JW McArthur, et al. (1981) Delayed menarche and amenorrhea of college athletes in relation to age of onset of training. JAMA 246 1559-1563
158. BL Drinkwater, K Nilson, CH Chesnut 3rd, et al. (1984) Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med 311 277-281
159. J Willi and S Grossmann (1983) Epidemiology of anorexia nervosa in a defined region of Switzerland. Am J Psychiatry 140 564-567
160. DM Schwartz and MG Thompson (1981) Do anorectics get well? Current research and future needs. Am J Psychiatry 138 319-323
161. WJ Swift (1982) The long-term outcome of early onset anorexia nervosa. A critical review. J Am Acad Child Psychiatry 21 38-46
162. RM Boyar, LD Hellman, H Roffwarg, et al. (1977) Cortisol secretion and metabolism in anorexia nervosa. N Engl J Med 296 190-193
163. PW Gold, H Gwirtsman, PC Avgerinos, et al. (1986) Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl J Med 314 1335-1342
164. WH Kaye, HE Gwirtsman, DT George, et al. (1987) Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J Clin Endocrinol Metab 64 203-208
165. T Moshang Jr and RD Utinger (1977) Low triiodothyronine euthyroidism in anorexia nervosa. RS Vigersky (Eds) Anorexia Nervosa New York, NY: Raven Press 263-270
166. PW Gold, W Kaye, GL Robertson and M Ebert (1983) Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa. N Engl J Med 308 1117-1123
167. SL Berga and TL Loucks (2006) Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci 1092 114-129
168. LA Soyka, S Grinspoon, LL Levitsky, et al. (1999) The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 84 4489-4496
169. JH Liu and SS Yen (1984) The use of gonadotropin-releasing hormone for the induction of ovulation. Clin Obstet Gynecol 27 975-982
170. D Ferriman and JD Gallwey (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21 1440-1447
171. GE Tagatz, RA Kopher, TC Nagel and T Okagaki (1979) The clitoral index: a bioassay of androgenic stimulation. Obstet Gynecol 54 562-564
172. CW Bardin and MB Lipsett (1967) Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 46 891-902
173. I Mowszowicz, E Melanitou, A Doukani, et al. (1983) Androgen binding capacity and 5 alpha-reductase activity in pubic skin fibroblasts from hirsute patients. J Clin Endocrinol Metab 56 1209-1213
174. U Schwartz, L Moltz, J Brotherton and J Hammerstein (1983) The diagnostic value of plasma free testosterone in non-tumorous and tumorous hyperandrogenism. Fertil Steril 40 66-72
175. KK Miller, W Rosner, H Lee, et al. (2004) Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab 89 525-533
176. E Carmine, F Rosato, A Janni, et al. (2006) Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 91 2-6
177. RJ Paulson, PC Serafini, JA Catalino and RA Lobo (1986) Measurements of 3 alpha,17 beta-androstanediol glucuronide in serum and urine and the correlation with skin 5 alpha-reductase activity. Fertil Steril 46 222-226
178. L Kennedy, AI Traub, AB Atkinson and B Sheridan (1987) Short term administration of gonadotropin-releasing hormone analog to a patient with a testosterone-secreting ovarian tumor. J Clin Endocrinol Metab 64 1320-1322
179. SB Bavdekar, RR Kasla, RC Parmar and GS Hathi (2001) Selective testosterone secreting adrenocortical carcinoma in an infant. Indian J Pediatr 68 95-97
180. J Derksen, SK Nagesser, AE Meinders, et al. (1994) Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 331 968-973
181. CI Friedman, GE Schmidt, MH Kim and J Powell (1985) Serum testosterone concentrations in the evaluation of androgen-producing tumors. Am J Obstet Gynecol 153 44-49
182. L Taylor, JW Ayers, MD Gross, et al. (1986) Diagnostic considerations in virilization: iodomethyl-norcholesterol scanning in the localization of androgen secreting tumors. Fertil Steril 46 1005-1010
183. C Bricaire, A Raynaud, A Benotmane, et al. (1991) Selective venous catheterization in the evaluation of hyperandrogenism. J Endocrinol Invest 14 949-956
184. R Azziz, LA Hincapie, ES Knochenhauer, et al. (1999) Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 72 915-925
185. PW Speiser, B Dupont, P Rubinstein, et al. (1985) High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 37 650-667
186. MI New, F Lorenzen, AJ Lerner, et al. (1983) Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 57 320-326
187. CA Stratakis, M Karl, HM Schulte and GP Chrousos (1994) Glucocorticosteroid resistance in humans. Elucidation of the molecular mechanisms and implications for pathophysiology. Ann N Y Acad Sci 746 362-374. discussion 374-376
188. O Koulouri and GS Conway (2008) A systematic review of commonly used medical treatments for hirsutism in women. Clin Endocrinol (Oxf) 68 800-805
189. RA Lobo, D Shoupe, P Serafini, et al. (1985) The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 43 200-205
190. S Evron, G Shapiro and YZ Diamant (1981) Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women. Fertil Steril 36 468-471
191. I Mowszowicz, F Wright, M Vincens, et al. (1984) Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem 20 757-761
192. RS Rittmaster (1994) Finasteride. N Engl J Med 330 120-125
193. IL Wong, RS Morris, L Chang, et al. (1995) A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 80 233-238
194. R Castello, F Tosi, F Perrone, et al. (1996) Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 66 734-740
195. E Diamanti-Kandarakis, A Mitrakou, S Raptis, et al. (1998) The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 83 2699-2705
196. P Moghetti, R Castello, C Negri, et al. (1995) Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil Steril 64 511-517
197. DK Wysowski, JP Freiman, JB Tourtelot and ML Horton 3rd. (1993) Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 118 860-864
198. K Hoeger, K Davidson, L Kochman, et al. (2008) The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 93 4299-4306
199. RS Legro, AR Kunselman, WC Dodson and A Dunaif (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 165-169
200. M Urbanek, RS Legro, DA Driscoll, et al. (1999) Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 96 8573-8578
201. RS Legro, D Driscoll, JF Strauss 3rd, et al. (1998) Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 95 14956-14960
202. I Stein and M Leventhal (1935) Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29 181-191
203. M Tamura, S Deb, S Sebastian, et al. (2004) Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril 81 1351-1356
204. JK Zawadzki and A Dunaif (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. A Dunaif, JR Givens, FP Haseltine, GR Merriam (Eds) Polycystic Ovary Syndrome Boston: Blackwell Scientific Publications 377-384
205. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 19-25
206. R Azziz (2006) Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 91 781-785
207. A Dunaif (1993) Insulin resistance in polycystic ovarian syndrome. Ann N Y Acad Sci 687 60-64
208. D Hoffman, K Klove and R Lobo (1980) The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women. Fertil Steril 42 853-861
209. S Franks (1995) Polycystic ovary syndrome. N Engl J Med 333 853-861
210. OA Kletzky, V Davajan, RM Nakamura, et al. (1975) Clinical categorization of patients with secondary amenorrhea using progesterone-induced uterine bleeding and measurement of serum gonadotropin levels. Am J Obstet Gynecol 121 695-703
211. S Venturoli, E Porcu, R Fabbri, et al. (1988) Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. Clin Endocrinol (Oxf) 28 93-107
212. V Imse, G Holzapfel, B Hinney, et al. (1992) Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. J Clin Endocrinol Metab 74 1053-1061
213. FJ Hayes, AE Taylor, KA Martin and JE Hall (1998) Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics. J Clin Endocrinol Metab 83 2343-2349
214. RB Barnes and RA Lobo (1985) Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. J Clin Endocrinol Metab 61 779-782
215. AJ Morales, GA Laughlin, T Butzow, et al. (1996) Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 81 2854-2864
216. AE Taylor, B McCourt, KA Martin, et al. (1997) Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 2248-2256
217. M Nagamani, T Van Dinh and ME Kelver (1986) Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 154 384-389
218. C Dorn, JF Mouillet, X Yan, et al. (2004) Insulin enhances the transcription of luteinizing hormone-beta gene. Am J Obstet Gynecol 191 132-137
219. EY Adashi, AJ Hsueh and SS Yen (1981) Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 108 1441-1449
220. MA Lawson, S Jain, S Sun, et al. (2008) Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women. J Clin Endocrinol Metab 93 2089-2096
221. RJ Chang (1984) Ovarian steroid secretion in polycystic ovarian disease. Semin Reprod Endocrinol 2 244
222. BL Wajchenberg, SS Achando, MM Mathor, et al. (1988) The source(s) of estrogen production in hirsute women with polycystic ovarian disease as determined by simultaneous adrenal and ovarian venous catheterization. Fertil Steril 49 56-61
223. D Chen, S Reierstad, M Lu, et al. (2009) Regulation of breast cancer-associated aromatase promoters. Cancer Lett 273 15-27
224. MJ Reed, A Singh, MW Ghilchik, et al. (1991) Regulation of oestradiol 17 beta hydroxysteroid dehydrogenase in breast tissues: the role of growth factors. J Steroid Biochem Mol Biol 39 791-798
225. JE Nestler (2000) Obesity, insulin, sex steroids and ovulation. Int J Obes Relat Metab Disord 24(Suppl 2), S71-S73
226. BC Fauser (1994) Observations in favor of normal early follicle development and disturbed dominant follicle selection in polycystic ovary syndrome. Gynecol Endocrinol 8 75-82
227. HD Mason, R Margara, RM Winston, et al. (1993) Insulin-like growth factor-I (IGF-I) inhibits production of IGF-binding protein-1 while stimulating estradiol secretion in granulosa cells from normal and polycystic human ovaries. J Clin Endocrinol Metab 76 1275-1279
228. R Homburg and CM Howles (1999) Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update 5 493-499
229. HL Judd, RE Scully, AL Herbst, et al. (1973) Familial hyperthecosis: comparison of endocrinologic and histologic findings with polycystic ovarian disease. Am J Obstet Gynecol 117 976-982
230. HE Cooper, WN Spellacy, KA Prem and WD Cohen (1968) Hereditary factors in the Stein-Leventhal syndrome. Am J Obstet Gynecol 100 371-387
231. D Ferriman and AW Purdie (1979) The inheritance of polycystic ovarian disease and a possible relationship to premature balding. Clin Endocrinol (Oxf) 11 291-300
232. SC Kent, CL Gnatuk, AR Kunselman, et al. (2008) Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 93 1662-1669
233. E Diamanti-Kandarakis, H Kandarakis and RS Legro (2006) The role of genes and environment in the etiology of PCOS. Endocrine 30 19-26
234. M Urbanek (2007) The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 3 103-111
235. Y Shi, H Zhao, Y Shi, et al. (2012) Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 44 1020-1025
236. A Dunaif, G Green, RG Phelps, et al. (1991) Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 73 590-595
237. GM Reaven, H Lithell and L Landsberg (1996) Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334 374-381
238. KJ Mather, F Kwan and B Corenblum (2000) Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 73 150-156
239. E Talbott, D Guzick, A Clerici, et al. (1995) Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15 821-826
240. DA Ehrmann, DR Liljenquist, K Kasza, et al. (2006) Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 48-53
241. A Dunaif and DT Finegood (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81 942-947
242. SS Reddy and CR Kahn (1989) Epidermal growth factor receptor defects in leprechaunism. A multiple growth factor-resistant syndrome. J Clin Invest 84 1569-1576
243. AA Bremer and WL Miller (2008) The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril 89 1039-1048
244. MA Kirschner, E Samojlik, M Drejka, et al. (1990) Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 70 473-479
245. DV Schapira, NB Kumar, GH Lyman and CE Cox (1990) Abdominal obesity and breast cancer risk. Ann Intern Med 112 182-186
246. N Kumar, A Cantor, K Allen and C Cox (2000) Android obesity at diagnosis and breast carcinoma survival: evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span, and survival from breast carcinoma. Cancer 88 2751-2757
247. KE Anderson, TA Sellers, PL Chen, et al. (1997) Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 79 494-499
248. PJ Campbell and JE Gerich (1990) Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab 70 1114-1118
249. DA Ehrmann (2005) Polycystic ovary syndrome. N Engl J Med 352 1223-1236
250. EM Velazquez, S Mendoza, T Hamer, et al. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43 647-654
251. J Nestler and D Jakubowicz (1996) Decreases in ovarian cytochrome P450c 17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335 617-623
252. E Velazquez, A Acosta and SG Mendoza (1997) Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 90 392-395
253. RS Legro, HX Barnhart, WD Schlaff, et al. (2007) Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356 551-566
254. S Palomba, A Falbo, F Zullo and F Orio Jr (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 30 1-50
255. T Tang, JM Lord, RJ Norman, et al. (2010) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev (1), CD003053
256. A Dunaif, D Scott, D Finegood, et al. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81 3299-3306
257. DA Ehrmann, DJ Schneider, BE Sobel, et al. (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 2108-2116
258. R Azziz, D Ehrmann, RS Legro, et al. (2001) Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 1626-1632
259. G Ghazeeri, WH Kutteh, M Bryer-Ash, et al. (2003) Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79 562-566
260. SH Belli, MN Graffigna, A Oneto, et al. (2004) Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 81 624-629
261. D Romualdi, M Guido, M Ciampelli, et al. (2003) Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 18 1210-1218
262. RA Wild, P Alaupovic and IJ Parker (1992) Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J Obstet Gynecol 166 1191-1196. discussion 1196-1197
263. DS Kiddy, D Hamilton-Fairley, A Bush, et al. (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36 105-111
264. DS Guzick, R Wing, D Smith, et al. (1994) Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 61 598-604
265. AM Clark, W Ledger, C Galletly, et al. (1995) Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 10 2705-2712
266. G Gitsch, E Hanzal, D Jensen and NF Hacker (1995) Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 85 504-508
267. SL Kjos, RK Peters, A Xiang, et al. (1998) Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 280 533-538
268. E Diamanti-Kandarakis, A Mitrakou, MM Hennes, et al. (1995) Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 44 525-531
269. A Lanzone, AM Fulghesu, F Cucinelli, et al. (1996) Preconceptional and gestational evaluation of insulin secretion in patients with polycystic ovary syndrome. Hum Reprod 11 2382-2386
270. JE Nestler, DJ Jakubowicz, WS Evans and R Pasquali (1998) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338 1876-1880
271. L Regan, EJ Owen and HS Jacobs (1990) Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 336 1141-1144
272. EY Adashi (1986) Clomiphene citrate-initiated ovulation: a clinical update. Semin Reprod Endocrinol 4 225-276
273. MF Mitwally and RF Casper (2001) Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75 305-309
274. A Badawy, A Mosbah and M Shady (2008) Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril 89 1209-1212
275. RS Legro, RG Brzyski, MP Diamond, et al. (2014) Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 371 119-129
276. T Tulandi, J Martin, R Al-Fadhli, et al. (2006) Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 85 1761-1765
277. D Hamilton-Fairley and S Franks (1990) Common problems in induction of ovulation. Baillieres Clin Obstet Gynaecol 4 609-625
278. GS Conway (2000) Premature ovarian failure. Br Med Bull 56 643-649
279. AE Taylor, JM Adams, JE Mulder, et al. (1996) A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. J Clin Endocrinol Metab 81 3615-3621
280. FJ Broekmans, MR Soules and BC Fauser (2009) Ovarian aging: mechanisms and clinical consequences. Endocr Rev 30 465-493
281. AG Myhre, M Halonen, P Eskelin, et al. (2001) Autoimmune polyendocrine syndrome type 1 (APS I) in Norway. Clin Endocrinol (Oxf) 54 211-217
282. WH Wallace, SM Shalet, EC Crowne, et al. (1989) Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol (R Coll Radiol) 1(2), 75-79
283. P Morice, R Thiam-Ba, D Castaigne, et al. (1998) Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy. Hum Reprod 13 660-663
284. J Bines, DM Oleske and MA Cobleigh (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14 1718-1729
285. J Byrne, JJ Mulvihill, MH Myers, et al. (1987) Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 317 1315-1321
286. RW Rebar and HV Connolly (1990) Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 53 804-810
287. LM Nelson, JN Anasti, LM Kimzey, et al. (1994) Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab 79 1470-1475
288. JH Check and B Katsoff (2008) Ovulation induction and pregnancy in a woman with premature menopause following gonadotropin suppression with the gonadotropin releasing hormone antagonist, cetrorelix: a case report. Clin Exp Obstet Gynecol 35 10-12
289. M Tartagni, E Cicinelli, G De Pergola, et al. (2007) Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertil Steril 87 858-861
290. G Dewald and J Spurbeck (1983) Sex chromosome anomalies associated with premature gonadal failure. Semin Reprod Endocrinol 1 79-92
291. JC Giltay, MG Ausems, I van Seumeren, et al. (2001) Short stature as the only presenting feature in a patient with an isodicentric (Y)(q11.23) and gonadoblastoma. A clinical and molecular cytogenetic study. Eur J Pediatr 160 154-158
292. M Manuel, PK Katayama and HW Jones Jr (1976) The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. Am J Obstet Gynecol 124 293-300
293. CH Gravholt, J Fedder, RW Naeraa and J Muller (2000) Occurrence of gonadoblastoma in females with Turner syndrome and Y chromosome material: a population study. J Clin Endocrinol Metab 85 3199-3202
294. E Peprah, W He, E Allen, et al. (2010) Examination of FMR1 transcript and protein levels among 74 premutation carriers. J Hum Genet 55 66-68
295. MD Wittenberger, RJ Hagerman, SL Sherman, et al. (2007) The FMR1 premutation and reproduction. Fertil Steril 87 456-465
296. LM Nelson (2001) Autoimmune ovarian failure: comparing the mouse model and the human disease. J Soc Gynecol Investig 8 S55-S57
297. NJ Wheatcroft, C Salt, A Milford-Ward, et al. (1997) Identification of ovarian antibodies by immunofluorescence, enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failure. Hum Reprod 12 2617-2622
298. CY Ramathal, IC Bagchi, RN Taylor and MK Bagchi (2010) Endometrial decidualization: of mice and men. Semin Reprod Med 28 17-26
299. EM Belsey and AP Pinol (1997) Menstrual bleeding patterns in untreated women. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 55 57-65
300. L Chiazze Jr, FT Brayer, JJ Macisco Jr, et al. (1968) The length and variability of the human menstrual cycle. JAMA 203 377-380
301. K Munster, L Schmidt and P Helm (1992) Length and variation in the menstrual cycle: a cross-sectional study from a Danish county. Br J Obstet Gynaecol 99 422-429
302. AE Treloar, RE Boynton, BG Behn and BW Brown (1967) Variation of the human menstrual cycle through reproductive life. Int J Fertil 12 77-126
303. G Rybo (1966) Menstrual blood loss in relation to parity and menstrual pattern. Acta Obstet Gynecol Scand 45(Suppl 7), 25-45
304. PJ Haynes, H Hodgson, AB Anderson and AC Turnbull (1977) Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol 84 763-768
305. JM Higham, PM O'Brien and RW Shaw (1990) Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 97 734-739
306. IS Fraser, G McCarron and R Markham (1984) A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 149 788-793
307. D de Ziegler, C Bergeron, C Cornel, et al. (1992) Effects of luteal estradiol on the secretory transformation of human endometrium and plasma gonadotropins. J Clin Endocrinol Metab 74 322-331
308. EM Belsey (1988) Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 38 181-206
309. DL Wilansky and B Greisman (1989) Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol 160 673-677
310. MP Hopkins, L Androff and AS Benninghoff (1988) Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol 159 1121-1122
311. EA Claessens and CA Cowell (1981) Acute adolescent menorrhagia. Am J Obstet Gynecol 139 277-280
312. YR Smith, EH Quint and RB Hertzberg (1998) Menorrhagia in adolescents requiring hospitalization. J Pediatr Adolesc Gynecol 11 13-15
313. MA van Eijkeren, GC Christiaens, AA Haspels and JJ Sixma (1990) Measured menstrual blood loss in women with a bleeding disorder or using oral anticoagulant therapy. Am J Obstet Gynecol 162 1261-1263
314. M Edlund, M Blomback, B von Schoultz and O Andersson (1996) On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 53 234-238
315. L Nilsson and G Rybo (1971) Treatment of menorrhagia. Am J Obstet Gynecol 110 713-720
316. JL Kirkland, L Murthy and GM Stancel (1992) Progesterone inhibits the estrogen-induced expression of c-fos messenger ribonucleic acid in the uterus. Endocrinology 130 3223-3230
317. GR DeVore, O Owens and N Kase (1982) Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding: a double-blind randomized control study. Obstet Gynecol 59 285-291
318. M Livio, PM Mannucci, G Vigano, et al. (1986) Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 315 731-735
319. LC Giudice and LC Kao (2004) Endometriosis. Lancet 364 1789-1799
320. SE Bulun (2009) Endometriosis. N Engl J Med 360 268-279
321. JL Simpson, S Elias, LR Malinak and VC Buttram Jr (1980) Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol 137 327-331
322. R Garry (2004) Is insulin resistance an essential component of PCOS? The endometriosis syndromes: a clinical classification in the presence of aetiological confusion and therapeutic anarchy. Hum Reprod 19(4), 760-768
323. I Brosens (2004) Endometriosis rediscovered? Hum Reprod 19 1679-1680. author reply 1680-1681
324. J Sampson (1927) Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 14 422-469
325. IE Sasson and HS Taylor (2008) Stem cells and the pathogenesis of endometriosis. Ann N Y Acad Sci 1127 106-115
326. D Hornung, IP Ryan, VA Chao, et al. (1997) Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. J Clin Endocrinol Metab 82 1621-1628
327. MT Dyson, D Roqueiro, D Monsivais, et al. (2014) Genome-wide DNA methylation analysis predicts an epigenetic switch for GATA factor expression in endometriosis. PLoS Genet 10(3), e1004158
328. RW Shaw (1992) An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team. Fertil Steril 58 265-272
329. A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of the North American Menopause Society. Menopause 7 76-86
330. P Vercellini, I Cortesi and PG Crosignani (1997) Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 68 393-401
331. K Takayama, K Zeitoun, RT Gunby, et al. (1998) Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 69 709-713
332. P Vercellini, L Trespidi, A Colombo, et al. (1993) A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 60 75-79
333. KG Waller and RW Shaw (1993) Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 59 511-515
334. DF Archer, K McIntyre-Seltman, WW Wilborn Jr, et al. (1991) Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol 165 317-320. discussion 320-322
335. A Amsterdam, M Knecht and K Catt (1981) Hormonal regulation of cytodifferentiation and intercellular communication in cultured granulosa cells. Proc Natl Acad Sci U S A 78 3000-3004
336. RK Ailawadi, S Jobanputra, M Kataria, et al. (2004) Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 81 290-296
337. S Soysal, ME Soysal, S Ozer, et al. (2004) The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 19 160-167
338. E Attar and SE Bulun (2006) Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 85 1307-1318
339. SE Bulun (2013) Uterine fibroids. N Engl J Med 369 1344-1355
340. EV Bouwsma, GK Hesley, DA Woodrum, et al. (2011) Comparing focused ultrasound and uterine artery embolization for uterine fibroids-rationale and design of the Fibroid Interventions: Reducing Symptoms Today and Tomorrow (FIRSTT) trial. Fertil Steril 96 704-710
341. SM McKinlay, DJ Brambilla and JG Posner (1992) The normal menopause transition. Maturitas 14 103-115
342. I den Tonkelaar, ER te Velde and CW Looman (1998) Menstrual cycle length preceding menopause in relation to age at menopause. Maturitas 29 115-123
343. HM Buckler, CA Evans, H Mamtora, et al. (1991) Gonadotropin, steroid, and inhibin levels in women with incipient ovarian failure during anovulatory and ovulatory rebound cycles. J Clin Endocrinol Metab 72 116-124
344. N Santoro, JR Brown, T Adel and JH Skurnick (1996) Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 81 1495-1501
345. SM McKinlay, NL Bifano and JB McKinlay (1985) Smoking and age at menopause in women. Ann Intern Med 103 350-356
346. DJ Torgerson, A Avenell, IT Russell and DM Reid (1994) Factors associated with onset of menopause in women aged 45-49. Maturitas 19 83-92
347. DJ Torgerson, RE Thomas, MK Campbell and DM Reid (1997) Alcohol consumption and age of maternal menopause are associated with menopause onset. Maturitas 26 21-25
348. DW Cramer, H Xu and BL Harlow (1995) Family history as a predictor of early menopause. Fertil Steril 64 740-745
349. MR Jiroutek, MH Chen, CC Johnston and C Longcope (1998) Changes in reproductive hormones and sex hormone-binding globulin in a group of postmenopausal women measured over 10 years. Menopause 5 90-94
350. F Labrie, A Belanger, L Cusan, et al. (1997) Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 82 2396-2402
351. S Feldman, A Shapter, WR Welch and RS Berkowitz (1994) Two-year follow-up of 263 patients with post/perimenopausal vaginal bleeding and negative initial biopsy. Gynecol Oncol 55 56-59
352. A Oldenhave, LJ Jaszmann, AA Haspels and WT Everaerd (1993) Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 168 772-780
353. F Kronenberg and R Barnard (1992) Modulation of menopausal hot flashes by ambient temperature. J Therm Biol 17 43-49
354. SS Yen (1977) The biology of menopause. J Reprod Med 18 287-296
355. RC Thurston, MR Sowers, B Sternfeld, et al. (2009) Gains in body fat and vasomotor symptom reporting over the menopausal transition: the study of women's health across the nation. Am J Epidemiol 170 766-774
356. R Raz and WE Stamm (1993) A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329 753-756
357. ES Siris, R Adler, J Bilezikian, et al. (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25 1439-1443
358. LS Richelson, HW Wahner, LJ Melton 3rd and BL Riggs (1984) Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311 1273-1275
359. L Nilas and C Christiansen (1987) Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab 65 697-702
360. C Christiansen (1996) Hormone replacement therapy and osteoporosis. Maturitas 23(Suppl), S71-S76
361. JE Manson, RT Chlebowski, ML Stefanick, et al. (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310 1353-1368
362. JE Manson (2014) Current recommendations: what is the clinician to do? Fertil Steril 101 916-921
363. WK Nicholson, AF Brown, J Gathe, et al. (1999) Hormone replacement therapy for African American women: missed opportunities for effective intervention. Menopause 6 147-155
364. RL Prentice and GL Anderson (2008) The women's health initiative: lessons learned. Annu Rev Public Health 29 131-150
365. American College of Obstetrics and Gynecology (2008) ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol 112 1189-1192
366. J Ness, WS Aronow, E Newkirk and D McDanel (2005) Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial. J Gerontol A Biol Sci Med Sci 60 460-462
367. M Hoffmann, M Hammar, KI Kjellgren, et al. (2005) Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 52 11-17
368. L Thunell, I Milsom, J Schmidt and LA Mattsson (2006) Scientific evidence changes prescribing practice: a comparison of the management of the climacteric and use of hormone replacement therapy among Swedish gynaecologists in 1996 and 2003. BJOG 113 15-20
369. VM Miller, DM Black, EA Brinton, et al. (2009) Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2 228-239
370. SA Shumaker, C Legault, SR Rapp, et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 2651-2662
371. S Hulley, D Grady, T Bush, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 605-613
372. RL Prentice, RT Chlebowski, ML Stefanick, et al. (2008) Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 167 1207-1216
373. JP Vandenbroucke (2009) The HRT controversy: observational studies and RCTs fall in line. Lancet 373 1233-1235
374. JV Lacey Jr, PJ Mink, JH Lubin, et al. (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 334-341
375. SA Shumaker, C Legault, L Kuller, et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 2947-2958
376. CJ Glueck, J Lang, T Hamer and T Tracy (1994) Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 123 59-64
377. DJ Cirillo, RB Wallace, RJ Rodabough, et al. (2005) Effect of estrogen therapy on gallbladder disease. JAMA 293 330-339
378. RT Chlebowski, AG Schwartz, H Wakelee, et al. (2009) Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 374 1243-1251
379. KA Martin and JE Manson (2008) Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab 93 4567-4575
380. BJ Riis, MA Hansen, AM Jensen, et al. (1996) Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 19 9-12
381. B Ettinger, A Pressman and A Van Gessel (2001) Low-dosage esterified estrogens opposed by progestin at 6-month intervals. Obstet Gynecol 98 205-211
382. SR Lindheim, SC Presser, EC Ditkoff, et al. (1993) A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60 664-667
383. JD Woodruff and JH Pickar (1994) Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 170 1213-1223
384. DF Archer, JH Pickar and F Bottiglioni (1994) Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 83 686-692
385. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273 199-208
386. SD Reed, KM Newton and AZ Lacroix (2004) Indications for hormone therapy: the post-Women's Health Initiative era. Endocrinol Metab Clin North Am 33 691-715
387. SM Harman, F Naftolin, EA Brinton and DR Judelson (2005) Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci 1052 43-56
388. MA Espeland, SR Rapp, SA Shumaker, et al. (2004) Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 2959-2968
389. SL Nand, MA Webster, R Baber and V O'Connor (1998) Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol 91 678-684
390. MO Korhonen, JP Symons, BM Hyde, et al. (1997) Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 176 377-380
391. KF McGonigle, BY Karlan, DA Barbuto, et al. (1994) Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. Gynecol Oncol 55 126-132
392. B Karlsson, S Granberg, M Wikland, et al. (1995) Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: a Nordic multicenter study. Am J Obstet Gynecol 172 1488-1494
393. O Bakos, P Smith and G Heimer (1994) Transvaginal ultrasonography for identifying endometrial pathology in postmenopausal women. Maturitas 20 181-189
394. S Granberg, P Ylostalo, M Wikland and B Karlsson (1997) Endometrial sonographic and histologic findings in women with and without hormonal replacement therapy suffering from postmenopausal bleeding. Maturitas 27 35-40
395. NE Avis (2008) Breast cancer survivors and hot flashes: the search for nonhormonal treatments. J Clin Oncol 26 5008-5010
396. L Holmberg, OE Iversen, CM Rudenstam, et al. (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100 475-482
397. RL Brunner, M Gass, A Aragaki, et al. (2005) Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med 165 1976-1986
398. VC Jordan and BW O'Malley (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25 5815-5824
399. HD Nelson, R Fu, JC Griffin, et al. (2009) Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 151 703-715. W-226-235
400. SR Rapp, MA Espeland, SA Shumaker, et al. (2003) Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 2663-2672
401. JP Bilezikian (2009) Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 122 S14-S21
402. JP Jansen, GJ Bergman, J Huels and M Olson (2009) Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin 25 1861-1868
403. G Bianchi and P Sambrook (2008) Oral nitrogen-containing bisphosphonates: a systematic review of randomized clinical trials and vertebral fractures. Curr Med Res Opin 24 2669-2677
404. S Bonnick, KG Saag, DP Kiel, et al. (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91 2631-2637
405. G Lodi, A Sardella, A Salis, et al. (2010) Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 68 107-110
406. M Gnant, B Mlineritsch, W Schippinger, et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360 679-691
407. DK Wysowski (2009) Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360 89-90
408. J Green, G Czanner, G Reeves, et al. (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 341 c4444
409. CR Cardwell, CC Abnet, MM Cantwell and LJ Murray (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304 657-663
410. SR Cummings, B Ettinger, PD Delmas, et al. (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359 697-708
411. NJ Bundred, P Kenemans, CH Yip, et al. (2012) Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res 14 R13